Ligand Pharmaceuticals (LGND) stock surged 5.07% on Friday, outperforming the broader market during the intraday trading session. The biopharmaceutical company's impressive rally followed the release of its Q4 2024 earnings results and positive analyst sentiment.
During the Q4 earnings call, Ligand Pharmaceuticals reported a 28% increase in royalty revenue and a 40% increase in core adjusted EPS for 2024. The company successfully launched two new commercial products, Veronaarma Auteuve and Merck's capaci, both exceeding sales expectations. Additionally, Ligand has a diversified portfolio of commercial stage royalty assets and a robust pipeline of development stage opportunities.
Adding to the positive sentiment, RBC Capital Markets raised its price target on Ligand Pharmaceuticals to $155 from $143, maintaining an Outperform rating. The analyst's bullish outlook reflects the company's strong financial position, restructured business model focused on profitable growth, and promising prospects for future growth drivers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。